HIT Consultant May 2, 2024
What You Should Know:
– Karius®, a leader in genomic diagnostics for infectious disease, announced today the closing of a $100 million Series C funding round.
– Co-led by Khosla Ventures and newcomers 5AM Ventures and Gilde Healthcare, the funding round also saw participation from existing investors like Softbank Vision Fund 2 and General Catalyst.
– This significant investment fuels Karius’ mission to revolutionize infectious disease diagnosis by expanding access to their innovative Karius Test®.
Karius Test: Revolutionizing Diagnostics
The Karius Test utilizes cutting-edge genomic analysis and artificial intelligence to identify over 1,000 pathogens from a single blood sample. This innovative approach streamlines diagnosis, eliminates the need for multiple tests, and provides valuable insights into complex infections.
Strengthening...
Today's Sponsors
Today's Sponsor